Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia

28 May 2019

Abstract excerpt

BACKGROUND: Resistance towards targeted cancer treatments caused by single nucleotide variations is a major issue in many malignancies. Currently, there are a number of available drugs for chronic myeloid leukaemia (CML), which are overcome by different sets of mutations. The main aim of this study was to explore if it can be possible to exploit this and create a treatment protocol that outperforms each drug on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Mathematical Biology Tumor Growth
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31138173
DOI: 10.1186/s12885-019-5690-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemiaPMID 31138173Read ↗

Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models.Semantic proximity Read ↗

Drug resistance in cancer: Principles of emergence and preventionSemantic proximity Read ↗

Dark selection for JAK/STAT-inhibitor resistance in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.Semantic proximity Read ↗

Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Multi-scale Predictions of Drug Resistance Epidemiology Identify Design Principles for Rational Drug Design.Semantic proximity Read ↗

Optimizing combination therapies with existing and future CML drugs.Semantic proximity Read ↗

Stochastic modeling of drug resistance in cancer.Semantic proximity Read ↗

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.Semantic proximity Read ↗

Beyond IC50-A computational dynamic model of drug resistance in enzyme inhibition treatment.Semantic proximity Read ↗

Data and implication based comparison of two chronic myeloid leukemia models.Semantic proximity Read ↗

Mathematical modeling suggests improved clinical outcomes of second-generation PARP inhibitors with reduced toxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.